MSB 3.72% 97.5¢ mesoblast limited

Ann: Trading Halt, page-109

  1. 14 Posts.
    lightbulb Created with Sketch. 2
    Pursuant to ASX Listing Rule 17.1, Mesoblast Limited ACN 109 431 870 (ASX: MSB; NASDAQ:
    MESO) (the Company) requests a trading halt in its securities effective immediately pending an
    announcement by the Company in relation to the United States Food and Drug Administration’s
    review of its Biologics License Application for RYONCIL® (remestemcel-L) in pediatric patients
    with steroid-refractory acute graft versus host disease.
    For the purposes of Listing Rule 17.1, the Company provides the following information:
    (a) the trading halt is requested pending an announcement in relation to the matters
    above;

    (b) the Company requests that the trading halt continues until it makes an announcement
    regarding the matters above which is expected to be on Monday, 5 October 2020; and
    (c) the Company is not aware of any reason why the trading halt should not be granted or
    of any other information necessary to inform the market about the trading halt.

    I believe we are still waiting for an ann from FDA - hence Halt till then,
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
97.5¢
Change
0.035(3.72%)
Mkt cap ! $1.110B
Open High Low Value Volume
94.0¢ 98.0¢ 92.0¢ $2.620M 2.735M

Buyers (Bids)

No. Vol. Price($)
36 128540 97.0¢
 

Sellers (Offers)

Price($) Vol. No.
97.5¢ 94900 17
View Market Depth
Last trade - 14.48pm 03/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.